



RUTGERS

iJOBS Virtual Site Visit: Daiichi Sankyo

February 28, 2024

12:00 PM



Chenchao Gao, PhD

Global Regulatory Program Manager

Daiichi Sankyo

cgao@dsi.com or gaochenchao@gmail.com

Dr. Chenchao Gao is currently a Global Regulatory Program Manager at Daiichi Sankyo on 4 programs including ADC products and Biospecifics. He also serves as the Alliance Team lead for a project with AstraZeneca.

Prior to joining Daiichi Sankyo, Chenchao was a Clinical Regulatory Senior Specialist at Seagen and supported the company to successfully obtain FDA approvals for multiple Oncology drugs (Tukysa and Adcetris). Before that, he used to work at Genentech, where he helped the TECENTRIQ program to obtain FDA approvals for 4 new INDs. Before joining Genentech, Chenchao was an ORISE fellow at the FDA.

Chenchao obtained his Ph.D. degree in Cellular and Molecular Pharmacology from Rutgers University in 2015. He was the president of Rutgers Chinese Student & Scholar Association (RCSSA) at Rutgers University.

Chenchao also served many key leadership positions in several non-profit organizations. He is currently an Executive Council (EC) Member of Sino American Pharmaceutical Professionals Association (SAPA) since and co-chaired or organized events, including Career Development, Scientific Symposium and Annual Conference.



Serom Lee, Ph.D

Associate Director of Global Market Research and Analytics in the Business Strategy and Analytics

Daiichi Sankyo

serlee@dsi.com
lee.serom@gmail.com

Serom Lee is an Associate Director of Global Market Research and Analytics in the Business Strategy and Analytics group at Daiichi Sankyo. She leads global market research projects and provides strategic insights for Daiichi Sankyo's antibody drug conjugates recently partnered with Merck including patritumab deruxtecan (HER3-DXd) and ifinatamab deruxtecan (I-DXd) that are currently in development across a variety of tumor types.

Prior to joining Daiichi Sankyo, Serom was a consultant in the oncology practice group at Lumanity where she led a number of projects for Biotech and Pharma clients including opportunity assessments, indication prioritizations, search and evaluation for in-licensing, and platform and portfolio strategy.

Before joining industry, Serom obtained her PhD in Biomedical Engineering at Rutgers University and also continued her post-doctoral research in Dr. Martin Yarmush's laboratory. She additionally gained exposure to the commercial side of life science through an internship at the university's Technology Transfer office.



Holly Hilton, Ph.D.

Senior Director in the Global Companion Diagnostics Department
Daiichi Sankyo Pharma
HHilton@DSI.com

Holly Hilton, PhD is a Senior Director in the Global Companion Diagnostics Department at Daiichi Sankyo Pharma. Her group is responsible for end-to-end processes for CDx Implementation in clinical studies, including responsibility to design and execute studies in support of CDx analytical and clinical utility validation studies in collaboration with Diagnostic partners.

Prior to joining Daiichi Sankyo, Holly was employed by PPD serving as Director Commercial Strategy lead where she collaborated with clinical operations, data analytics, feasibility, recruitment strategy and other functions to enhance the clinical trial enrollment strategies. While at PPD she also served for as a Director, Biomarker and Translational Sciences coordinating Biomarker services and co-developing internal precision medicine initiative to connect lab testing, clinical study, and regulatory activities. Prior to this Holly was employed by Hoffmann- La Roche pharma where she held a variety of positions of increasing responsibility including heading the Roche tissue biobank, Lab Head for Expression analysis and was eventually the Head of Disease and Translational Genomics at Roche Nutley, NJ. Holly has a bachelor's degree from Creighton University and obtained her PhD in Genetics from Rutgers University, New Brunswick, New Jersey.



Carolyn Federici, PhD

Director, Global Oncology Medical Affairs
Daiichi Sankyo
cfederici@dsi.com

Carolyn Federici is a director in global oncology medical affairs at Daiichi Sankyo where she leads global medical strategy for ifinatamab deruxtecan (I-DXd) in gastrointestinal (GI) and genitourinary (GU) cancer indications. She serves on the fellowship leadership committee in global medical affairs supporting the Rutgers PharmD fellowship program at DS. She joined DS in 2021 as a global scientific engagement lead. Prior to DS, she spent 7 years within medical communications agencies developing medical strategy and

content for multiple pharmaceutical clients in oncology. She started her career as an analyst for the US Department of Defense, where she gained experience in technical analysis and writing.

She earned a PhD in chemical and biochemical engineering from Rutgers University in 2011 where her doctoral work focused on polymeric drug delivery to solid tumors. She holds a BS in chemical engineering from Lafayette College in Easton, PA.